Search
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawnZotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd. … [A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's.[A31857] Zotepine was never approved by the FDA.
Aztreonam
go.drugbank.com/drugs/DB00355ApprovedInvestigationalIt may cause a superinfection with gram-positive organisms. … A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum.
Products: AZBIOS® 1G POLVO PARA RECONSTITUIR A SOLUCION INYECTABLE, AZTREONAM 1G POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLESelpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers.
Synonyms: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalAbout 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which … Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme.
Synonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. … Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigationalRisankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23).
Dehydroascorbic acid
go.drugbank.com/drugs/DB08830ExperimentalCurrently dehydroascorbic acid is an experimental drug with no known approved indications.
Foreskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedAlso known as Dermagraft, this device is a cryopreserved human fibroblast-derived dermal substitute. … Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427].
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnThe compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. … A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen.
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigationalZolbetuximab (previously claudiximab)[A264748] is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas